common glp-1 drugs Medications for Weight Loss List of approved and pending
Description
The longer answer depends on which clinical trial data you reference, your prior experience with GLP-1 agonists, and your individual tolerance profile
In some people, weight loss can lead to looser or sagging skin
The programme spans multiple trials targeting distinct endpoints: On 21 May 2026 Eli Lilly reported topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial and the programme's first Phase 3 efficacy readout: in 2,339 adults, mean weight loss at the 80-week primary endpoint reached 19.0% (4mg), 25.9% (9mg), and 28.3% (12mg) versus 2.2% for placebo (Eli Lilly investor release
Impact on glycated haemoglobin and body weight changes after stopping tirzepatide for 4 weeks in the SURPASS-1 monotherapy trial
